Viridian Therapeutics Inc VRDN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Viridian Therapeutics Says FDA Approves Lumvoa to Treat Thyroid Eye Disease
Viridian Shares Fall After Competing Amgen Eye Drug Performs Well
Viridian Therapeutics in Royalty Financing Deal With DRI Healthcare for Up to $300 Million
Trading Information
- Previous Close Price
- $28.49
- Day Range
- $28.60–30.38
- 52-Week Range
- $13.18–34.29
- Bid/Ask
- $29.59 / $32.00
- Shares Outstanding
- 113.56M
- Market Cap
- $3.43B
- Volume/Avg
- 4M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 119.95
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 252
Valuation
Metric | VRDN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.10 |
Price/Sales | 119.95 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | VRDN |
|---|---|
Quick Ratio | 14.06 |
Current Ratio | 14.46 |
Interest Coverage | −19.03 |
Quick Ratio
VRDN
Profitability
Metric | VRDN |
|---|---|
Return on Assets (Normalized) | −45.74% |
Return on Equity (Normalized) | −81.82% |
Return on Invested Capital (Normalized) | −55.35% |
Return on Assets
VRDN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|CWtKwR> | LOCK|>mbNq | $140B | |||
| Moderna Inc MRNA | LOCK|$F@$?w | LOCK|CXB | $109B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|W$tQ%x | LOCK|pT<nl | $95B | |||
| argenx SE ADR ARGX | LOCK|#tbhd>^ | LOCK|&T | $60B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|FR@WmF | LOCK|%P% | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|>&ZK^@T | LOCK|&G>?G | $31B | |||
| Incyte Corp INCY | LOCK|n#Gj^N$ | LOCK|C^ | $25B | |||
| BioNTech SE ADR BNTX | LOCK|lMnY<h | LOCK|z$Z | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|v^N<S# | LOCK|!$rRF | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|s!f@mK | LOCK|!> | $16B |
United States